Aerin Medical Secures $32.5 Million in Funding for Innovative ENT Solutions

Aerin Medical, a pioneer in non-invasive solutions for chronic nasal airway conditions, has successfully raised $32.5 million in a recent funding round aimed at enhancing its innovative product offerings and expanding its market reach. With a steadfast mission to provide ENT physicians with effective and patient-friendly treatments, Aerin Medical offers FDA-cleared solutions like VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis. These cutting-edge products utilize the company’s proprietary, temperature-controlled technology, enabling ENT specialists to deliver significant symptom relief through in-office procedures that utilize only local anesthetic. The funds raised in this round will be allocated toward further developing Aerin's product portfolio and accelerating clinical research efforts, ensuring the introduction of more groundbreaking treatments to benefit patients suffering from chronic nasal conditions. This funding marks a pivotal moment in Aerin Medical's growth trajectory, as the company strives to fulfill its commitment to improving the quality of life for individuals afflicted with these conditions. As Aerin Medical continues to innovate and expand, it remains dedicated to forging strong partnerships with ENT specialists and investing in the future of ear, nose, and throat healthcare. For more updates and detailed information about their products, visit Aerin Medical’s website at www.aerinmedical.com.